Asia Green Biotechnology Corp.

ASIA

CA04522C1041

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 01:34:38 2024-02-06 pm EST			5-day change	1st Jan Change
0.015 ^CAD	+50.00%		-.--%	+50.00%

May. 24	Asia Green Biotechnology Corp. Announces Vincent Ghazar Resigns as Director	CI
May. 24	Asia Green Biotechnology Corp. Announces Resignation of Vincent Ghazar as Chief Financial Officer	CI

Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2020

March 14, 2021

Asia Green Biotechnology Corp. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced net loss was CAD 552,833 compared to CAD 767,180 a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.03 a year ago.

Latest news about Asia Green Biotechnology Corp.

Asia Green Biotechnology Corp. Announces Vincent Ghazar Resigns as Director	May. 24	CI
Asia Green Biotechnology Corp. Announces Resignation of Vincent Ghazar as Chief Financial Officer	May. 24	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	May. 23	CI
Asia Green Biotechnology Corp. Announces Discontinuation of Any Further Activities in Asia, in Particular, in Cambodia and Thailand	Apr. 12	CI
Burton Growers Ltd. & Green Sight Agri-Holdings Inc. entered into a non-binding letter of intent to acquire Asia Green Biotechnology Corp. for CAD 4 million in a reverse merger transaction.	Feb. 20	CI
Asia Green Biotechnology Corp. announced that it expects to receive CAD 1.5 million in funding	Feb. 19	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 29	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-28	CI
Asia Green Biotechnology Corp. Announces Passing of Johannes Kingma, Director	23-08-15	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30	CI
Asia Green Biotechnology Corp. Partners with Pathway Rx Inc. to Pursue Clinical Trials Activities in the Development of A Migraine Treatment Utilizing Cannabis and Hemp Extracts Controlled by Pathway Inc	23-04-26	CI
Asia Green Biotechnology Corp. Announces Resignation of Daryl Hudson as Director	23-04-26	CI
Asia Green Biotechnology Corp. Auditor Raises 'Going Concern' Doubt	23-04-05	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-05	CI
Asia Green Biotechnology Corp. Proceeds to Next Phase of Migraine Clinical Study	23-01-23	CI
Asia Green Biotechnology Corp. Proceeding to Next Phase of Migraine Clinical Study; Extending Financing Arrangement	23-01-23	MT
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-27	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-17	CI
Asia Green Biotechnology Corp. Auditor Raises 'Going Concern' Doubt	22-05-01	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-01	CI
2,003,090 Common Shares of Asia Green Biotechnology Corp. are subject to a Lock-Up Agreement Ending on 24-JAN-2022.	22-01-23	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-25	CI
Asia Green Biotechnology Corp. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-30	CI
Asia Green Biotechnology Corp. to Fund Initial Human Clinical Trials for Treatment of Migraine Conditions	21-08-10	CI

Chart Asia Green Biotechnology Corp.

Duration

Period

More charts

Company Profile

Asia Green Biotechnology Corp. is a Canada-based early-stage international agro-technology company. The Company is focused on the development, evaluation, testing, application and, ultimately, supply to the market of organic hybridization technology and certain products derived from that technology (the Technology). The Company is engaged in planting, growth and harvesting of new and valuable strains of hemp and related crops in commercial quantities under the terms of the license agreement with InPlanta Biotechnology Inc. (InPlanta) and the evaluation and development of medicinal and related cannabinoid extracts under the terms of license agreements with Swysh Inc. (Swysh), and Pathway Rx Corp (Pathway Rx). It is in the process of establishing and implementing research and development programs in Cambodia and Thailand and continues to evaluate the potential to expand its business operations to other countries in the region.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
ASIA GREEN BIOTECHNOLOGY CORP.	+50.00%	399K
DONG-E-E-JIAO CO.,LTD.	+42.07%	6.23B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-21.20%	4.19B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+5.38%	3.32B
TASLY PHARMACEUTICAL GROUP CO., LTD	-16.98%	2.91B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-5.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+45.47%	1.94B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-12.67%	1.59B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-3.91%	1.58B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+44.56%	1.49B